NIAID AIDS Vaccine Selection Committee
NIAID establishes 12-member committee to help in decisions on which potential AIDS vaccines now being tested in laboratories are "promising enough" to be tested in humans. In addition, committee will recommend minimum guidelines manufacturers must meet for eligibility for Phase I trials and for being considered for Phase II studies. Committee members include PMA VP-Medical and Regulatory Affairs John Petricciani and FDA Biological IND Division Deputy Director Janet Woodcock.
You may also be interested in...
The US FDA appears to have concerns about the device used to administer the vaccine.
The US Medicare agency has released a quick-start guide for laboratory certification.
Washington State Ecology Mulls ‘Safer’ Definition While Exploring Phthalate Alternatives In Fragrances
Marissa Smith, senior regulatory toxicologist in the Washington Department of Ecology’s Hazardous Waste and Toxics Reduction program, discusses what’s next for the state’s inaugural Safer Products go-round. “How we define ‘safer’ is really going to be the lynchpin of this whole process,” she says.